Arrowhead Pharma stock rating reiterated at Buy by TD Cowen

Arrowhead reported EPS $0.22 vs $0.12 expected (83% surprise) and revenue $264M vs $227.61M expected, while its stock has surged ~336% over the past year to $60.51 (market cap $8.46B). Analysts show mixed reactions: TD Cowen reiterated Buy, BofA cut its PT to $81 from $84 citing lower probability for obesity programs, Leerink kept Market Perform at $61, and Goldman kept Neutral at $85; consensus PTs imply ~32% upside but InvestingPro flags the stock above fair value. Pipeline updates were mixed—WVE-007 (ARO-INHBE) monotherapy results disappointed versus dose expectations, prompting expanded hypothesis-generating and planned Phase II studies (including ARO-ALK7 and combination trials with tirzepatide); key catalysts include sHTG data in Q3 and additional H2 detail.

Analysis

Arrowhead’s INHBE/ALK7 programs look to be migrating from a standalone obesity monotherapy story into a niche adjunctive and indication-specific play (T2D, MASH, maintenance after GLP-1 induction). That shift favors a partnership/licensing value realization path and increases optionality for pharma buyers who want combo capabilities without competing on first-line GLP economics. A corollary: companies providing the GLP backbone (tirzepatide, semaglutide) become de facto gatekeepers — trial timing, label and payer negotiating dynamics will materially influence peak sales multiples.

Near-term market moves will be driven by binary clinical readouts and sHTG/liver-fat signals over the next 3–12 months; those data will reprice probability-of-success assumptions and likely drive volatile 30–60% moves in either direction. Key structural risks include inadequate monotherapy effect vs. GLP comparators, combination safety/tolerability surprises, and longer regulatory paths for MASH that move value from near-term revenue to long-duration royalties. A second-order timing risk: positive combo signals could compress pricing power if payers push for combination discounts or prefer step-through therapy.

Consensus appears to underweight a durable ‘‘maintenance/adjunct’’ revenue stream but may be overpaying for monotherapy upside baked into models today. That creates a two-way trade: short exposure to names whose recent pop was driven purely by monotherapy hype, and selective long exposure to platform owners with clear partnership optionality and multiple upcoming catalysts. Position sizing and explicit protection around the next 3–9 month readouts are essential — success should re-rate materially, failure will likely trigger >40% downside in high-beta names.

Key Decisions for Investors

• Pair trade (3–12 months): Long ARWR equity (size 1–2% NAV) + buy 9-month put at ~30% OTM as hedge; Short WVE equity or buy 6–9 month puts (size 0.5–1% NAV). R/R: asymmetric — ~30–50% upside on ARWR if Phase II/combo signals are positive; downside capped by put; WVE downside potential >40% if dose-response skepticism persists.
• Options collar (6–12 months) on ARWR: buy 12-month call spread (buy ITM/near-ATM call, sell higher-strike call) financed partially by selling 6–9 month OTM puts. Target cost ~2–4% NAV exposure with 2–4x upside if positive readouts; max loss limited to premium and assigned short-put risk.
• Tactical long SRPT (6–12 months), small size (0.5–1% NAV) as lower-beta exposure to partner-led upside; write 3–6 month covered calls to monetize position and protect against headline-driven mean reversion. R/R: modest upside (20–40%) with income cushioning a clinical volatility drawdown.
• Risk management: set alerts for next sHTG/liver-fat readout windows and pre-declare stop-losses at -30% on unhedged equity exposure or rebalance into options protection within 2 weeks of each major readout. Keep aggregate biotech event-risk exposure capped at 8–12% NAV until 12 months of catalyst visibility is established.